Bank of Montreal’s LAVA Therapeutics LVTX Stock Holding History

Bank of Montreal’s Portfolio LVTX Stock Details LVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-89,600	Closed	-$530K	–	4018
2022 Q4	$530K	Buy	+89,600	New	+$411K	﹤0.01%	2576

Other funds holding LVTX

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of Montreal's LVTX Position: Q1 2023 in Review

Bank of Montreal sold out of LAVA Therapeutics (LVTX) in Q1 2023, closing a stake of 89,600 shares — an estimated $530K sold.

Bank of Montreal first reported a position in LVTX in Q4 2022 and held it in 1 quarter. The position peaked at $530K in Q4 2022. 19 funds tracked by Wall St. Rank hold LVTX as of Q1 2023.

Bank of Montreal reported no remaining LAVA Therapeutics position as of Q1 2023 after selling out during the quarter.
Bank of Montreal sold 89,600 LAVA Therapeutics shares in Q1 2023, an estimated $530K.
Bank of Montreal first reported a position in LAVA Therapeutics in Q4 2022 and held it in 1 quarter.
Bank of Montreal's LAVA Therapeutics position peaked at $530K in Q4 2022.
19 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q1 2023.

Based on Bank of Montreal's 13F filing for Q1 2023, filed 13 Jun 2024.